Notably, the cumulative risk of endometrial cancer during years 5 to 14 from breast cancer diagnosis was 3.1% for women who received 10 years of tamoxifen versus 1.6% for women who received 5 years of tamoxifen.
The mortality rate for years 5 to 14 was 12.2% for women who received 10 years of tamoxifen versus 15% for women who received 5 years of tamoxifen, for an absolute mortality reduction of 2.8%.
Aromatase Inhibitors Patients on tamoxifen more frequently developed endometrial cancer and cerebrovascular accidents, whereas patients on anastrozole had more fracture episodes.
The frequency of myocardial infarction was similar in both groups.